Render Target: STATIC
Render Timestamp: 2024-10-04T09:39:56.839Z
Commit: f04ddd7fea9fb3592f59f61482fcb94610d25cbe
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77

DOCK180 (C4C12) Rabbit mAb #4846

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H M R
    SENSITIVITY Endogenous
    MW (kDa) 215
    Source/Isotype Rabbit
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Immunoprecipitation 1:100

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    DOCK180 (C4C12) Rabbit mAb recognizes endogenous levels of total DOCK180 protein.

    Species Reactivity:

    Human, Mouse, Rat

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to the carboxy-terminal sequence of human DOCK180.

    Background

    DOCK180 and its partner, ELMO1, interact directly with one another to form an atypical two-part guanine nucleotide exchange factor (GEF) for the small GTPase Rac (1). Rac activation occurs in association with p130 Cas and Crk, which form a complex with DOCK180 that is targeted to focal adhesions (1,2). DOCK180 is also recruited to the plasma membrane by binding to phosphoinositides (3). ELMO1 may function as an inhibitor of proteasome-dependent degradation of DOCK180 at the plasma membrane to regulate reorganization of the actin cytoskeleton (4). Localized Rac activation allows actin nucleation via WAVE family proteins, signaling to integrins, formation of lamellipodia and filopodia, and regulation of processes such as phagocytosis and cell migration (5-7).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    U.S. Patent No. 7,429,487, foreign equivalents, and child patents deriving therefrom.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.